Breaking News
Roche
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Roche Showcases Commitment to Advancing Innovative Diagnostic Solutions
May 17 2023
Roche announced today that it will be showcasing innovative laboratory solutions and digital diagnostics through […]
FDA Accepts Application for Roche’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 9 2023
Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s […]
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
April 17 2023
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease
March 22 2023
Roche announced today that it has entered into a collaboration with Eli Lilly and Company […]
Roche launches Two New Antibodies to Identify Key Clinical Mutations in Patients with Brain Cancer
February 24 2023
Roche announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and […]
Roche’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People with Retinal Vein Occlusion (RVO)
February 10 2023
Roche today announced positive new data from two global phase III studies, BALATON and COMINO, […]
Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, a Rare Life-threatening Blood Condition
February 7 2023
Roche has announced positive results from the global phase III COMMODORE 2 study, evaluating the […]
CARsgen Announces Collaboration Agreement with Roche to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
February 1 2023
CARsgen Therapeutics, a company focused on innovative therapies for the treatment of hematologic malignancies and […]
Roche launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-variant
January 26 2023
Roche and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that […]
Sysnav Healthcare Announces a Multi-year Collaboration with Roche
January 25 2023
Sysnav Healthcare and Roche enter a partnership to facilitate development of industry-standard outcome measurements in […]
New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration
December 14 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and […]
European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss
September 20 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) […]
PhoreMost Enters Multi-project Drug Target Discovery Collaboration With Roche
September 6 2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced […]
Roche Launches a Digital PCR System, a Powerful New Diagnostics Platform in the Fight Against Cancer and Other Diseases
August 23 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Digital LightCyclerⓇ System, Roche’s first […]
Roche Launches COVID-19 Test That Detects and Differentiates the Emerging Variant of Interest BA.2.75
August 22 2022
Roche (SIX: RO, ROG;OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 test for […]
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
August 18 2022
Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary […]
FDA Accepts Supplemental Biologics License Application for Roche’s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma
August 16 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to SARS-CoV-2
August 15 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® IGRA SARS-CoV-2 test […]
Roche Receives FDA Approval for VENTANA MMR RxDx Panel to Identify dMMR Solid Tumour Patients and pMMR Endometrial Cancer Patients Eligible for KEYTRUDA
August 11 2022
Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of a […]
CHMP Recommends EU Approval of Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss
July 25 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
Roche Launches Innovative Dual Antigen and Antibody Diagnostic Test Supporting the Fight to Eliminate the Hepatitis C Virus
July 19 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® HCV Duo […]
Roche Launches New BenchMark ULTRA PLUS System for Cancer Diagnostics Enabling Timely, Targeted Patient Care
June 29 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its […]
Roche Launches Human Papillomavirus (HPV) Self-sampling Solution, Expanding Cervical Cancer Screening Options
June 16 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) […]
European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer
June 9 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) […]
European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma
June 8 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional […]
New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma
May 27 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational […]
Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma
May 26 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted […]
Roche Develops Unique PCR Tests to Detect the Monkeypox Virus
May 26 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus […]
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
May 24 2022
KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for […]
Roche Enters Partnership With the Global Fund to Support Low- and Middle-income Countries in Strengthening Critical Diagnostics Infrastructure
May 12 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund […]
CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer
April 25 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults
April 4 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer
March 30 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III SKYSCRAPER-02 study, evaluating the […]
Roche Announces Collaboration With Bristol Myers Squibb to Advance Personalised Healthcare Through Digital Pathology Solutions
March 25 2022
Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced that it has entered into a collaboration with Bristol […]
Roche Provides Molecular Testing Solutions to Identify and Differentiate SARS-CoV-2 Omicron Variants of Concern
March 17 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a subsidiary within the Roche Diagnostics division, […]
New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA)
March 16 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for Evrysdi® (risdiplam) in spinal muscular atrophy […]
New Two-year Data for Roche’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss
February 11 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase […]
FDA Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
January 31 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Roche’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age with Spinal Muscular Atrophy (SMA)
January 25 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Roche Launches the Cobas® Pulse System, an Industry First Professional Blood Glucose Management Solution with Mobile Digital Health Capabilities to Improve Patient Care
January 12 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® pulse system in […]
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
January 12 2022
Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 […]
Roche Introduces Cobas Infinity Edge, a New Open Digital Ecosystem for Point of Care Professionals, Driving Improved Patient Outcomes and Operational Efficiencies in Healthcare
January 11 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced cobas ® infinity edge, a secure and […]
PRISM BioLab Enters Multi-Project Drug Discovery Collaboration with Roche and Genentech
January 5 2022
PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery […]
Roche Launches the AVENIO Edge System to Simplify and Automate Next-generation Sequencing Sample Preparation, Reduce Human Error and Advance Precision Medicine
December 13 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the AVENIO Edge System, […]
Roche to Launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in Countries Accepting the CE Mark to Enable Rapid Differentiation of Viral Respiratory Infections
December 6 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu […]
Roche Has Rapidly Developed Additional Testing Options to Differentiate Mutations in the Omicron SARS-CoV-2 Variant
December 3 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche […]
NHS Deal On Spinal Muscular Atrophy (SMA) First Home Treatment
November 19 2021
A life-changing drug that can improve mobility in children and adults with a rare genetic […]
Roche Launches Cobas 5800, a New Molecular Diagnostics System to Expand Access to Testing and Improve Patient Care
November 18 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® 5800 System, a new […]
Roche Launches Comprehensive Genomic Profiling Kit to Expand Access to Personalised Cancer Research
October 25 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has launched the AVENIO Tumor Tissue […]
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer
October 18 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]
Roche Announces PathAI Collaboration for Artificial Intelligence-based Digital Pathology Applications for Improved Patient Care
October 15 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, […]
Roche Opens Access to Pathology Imaging Tools to Improve Patient Care
September 15 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the introduction of the Roche Digital Pathology Open […]
First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK
August 20 2021
Following on from a thorough review of the evidence carried out by the MHRA, and […]
Roche Receives FDA Approval for First Companion Diagnostic to Identify dMMR Solid Tumour Patients Eligible for Anti-PD-1 Immunotherapy
August 19 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval […]
FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
July 29 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A
July 19 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the […]
Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
June 29 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved […]
New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year
June 11 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of […]
European Commission Approves Venclyxto-based Combinations for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy
May 25 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto […]
Roche’s Tecentriq Approved by European Commission
May 5 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq […]
New Roche Data at 2021 AAN Highlight Neuroscience Portfolio
April 9 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and […]
Roche Launches Elecsys Epstein-barr Virus (Ebv) Immunoassay Panel
March 31 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Elecsys® EBV panel has launched […]